3-Hydroxyphencyclidine (3-HPC), a breakdown product of phencyclidine (PCP), is growing attracting clinical focus due to sparse data suggesting unique physiological properties. Preliminary studies demonstrate that 3-HPC may display separate impacts on the brain system, possibly playing a role to some of the unexplained symptoms linked with PCP expos